References

Antibody drug conjugate: the “biological missile” for targeted cancer therapy

10.1038/s41392-022-00947-7 · 2022 · External reference

Early intervention in cancer using monoclonal antibodies and other biological ligands: micropharmacology and the “binding site barrier”

1992 · External reference

Single-cell spatial pharmacobiology identifies conserved stromal barriers to therapeutic antibody delivery in human solid tumors

10.1038/s41587-026-03152-x · 2026 · External reference

Use of panitumumab-IRDye800 to image cutaneous head and neck cancer in mice

10.1177/0194599813482290 · 2013 · External reference

Safety and tumor specificity of cetuximab-IRDye800 for surgical navigation in head and neck cancer

10.1158/1078-0432.ccr-14-3284 · 2015 · External reference

Co-administered antibody improves penetration of antibody-dye conjugate into human cancers with implications for antibody-drug conjugates

10.1038/s41467-020-19498-y · 2020 · External reference

Spatial determinants of antibody-drug conjugate SHR-A1811 efficacy in neoadjuvant treatment for HER2-positive breast cancer

10.1016/j.ccell.2025.03.017 · 2025 · External reference

Spatial analysis of drug absorption, distribution, metabolism, and toxicology using mass spectrometry imaging

10.1016/j.bcp.2022.115080 · 2022 · External reference

Method to visualize the intratumor distribution and impact of gemcitabine in pancreatic ductal adenocarcinoma by multimodal imaging

10.1021/acs.analchem.1c04579 · 2022 · External reference

PL02.11 normalized membrane ratio of TROP2 by quantitative continuous scoring is predictive of clinical outcomes in TROPION-lung 01

10.1016/j.jtho.2024.09.015 · 2024 · External reference